TYRA · CIK 0001863127 · operating
Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines targeting fibroblast growth factor receptor (FGFR) biology. The company has created SNÅP, a proprietary platform designed to enable drug design through iterative molecular snapshots that predict genetic alterations, facilitating the development of therapies for oncology and genetically defined conditions. The platform supports the company's pipeline of FGFR-targeted candidates across multiple therapeutic areas.
The company's lead product candidate, TYRA-300, is currently in clinical trials for metastatic urothelial carcinoma and other solid tumors, with a separate development program evaluating the candidate for skeletal conditions including achondroplasia, hypochondroplasia, and thanatophoric dysplasia. Additional pipeline candidates include TYRA-200, which is in clinical trial for bile duct and solid tumors, and TYRA-430 for hepatocellular carcinoma treatment. As a clinical-stage company, Tyra does not currently generate product revenues.
Based in Carlsbad, California, Tyra operates with approximately 60 full-time employees. The company was incorporated in Delaware in 2018 and is listed on the Nasdaq with a market capitalization of $1.8 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.51 | $-1.51 | +6.8% | |
| 2023 | $-1.62 | $-1.62 | -22.7% | |
| 2022 | $-1.32 | $-1.32 | — | |
| 2021 | — | — | — |